<unk>  is a humanized monoclonal antibody fragment (Fab) that is FDA approved for the treatment of patients treated with dabigatran when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.   Common adverse reactions include headache (5%) in healthy volunteers and hypokalemia, delirium, constipation, pyrexia, and pneumonia (5%) in patients.
Idarucizumab
Risankizumab
Mogamulizumab
Caplacizumab
Tildrakizumab
Ixekizumab
Motavizumab
Emicizumab